The IL11 Knockout AGS Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line, designed for targeted disruption of the IL11 gene. This loss-of-function model ablates interleukin-11 (IL-11) cytokine expression, eliminating IL-11-dependent signaling. The polyclonal population retains a heterogeneous knockout background, suitable for ensemble assays requiring population-level responses.
The AGS cell line originates from a primary gastric adenocarcinoma resected from a female patient and serves as a well-characterized epithelial model of gastric cancer. These cells exhibit rapid proliferation, anchorage-independent growth, and invasive capacity typical of poorly differentiated gastric carcinoma. The AGS line is used in preclinical oncology research to investigate gastric cancer pathogenesis, evaluate therapeutics, and dissect tumor signal transduction. Its epithelial origin and retained responsiveness to cytokines such as IL-11 and TGF-?? make it a relevant system for studying inflammation-associated gastric carcinogenesis.
IL-11 encodes a pleiotropic cytokine that signals through a heterodimeric receptor complex composed of the ligand-specific IL11RA subunit and the common signal-transducing gp130 co-receptor. Ligand binding induces activation of receptor-associated Janus kinases JAK2 and TYK2, which phosphorylate and activate STAT3, as well as the ERK1/2 and AKT kinases through MAPK/ERK and PI3K/AKT pathways, respectively. This signaling network is under the control of upstream regulators such as TGF-??, IL-1??, TNF-??, hypoxia, and mechanical stress. Downstream, activated STAT3, ERK1/2, and AKT transcriptionally regulate pro-survival factors (e.g., BCL2), extracellular matrix remodeling enzymes (MMP2, MMP9), fibrogenic genes (COL1A1, ACTA2), and inflammatory mediators (CXCL8). IL-11 therefore functions as a central node linking inflammatory and mechanical cues to cellular hyperplasia, matrix deposition, and tumor invasiveness.
In the context of AGS gastric cancer cells, IL-11-mediated signaling promotes a malignant phenotype characterized by enhanced cell proliferation, resistance to apoptosis, and increased migratory and invasive potential. Disruption of IL11 in this cell background is expected to impair the autocrine and paracrine loops that sustain JAK/STAT3, MAPK/ERK, and PI3K/AKT activation, leading to reduced expression of pro-survival and pro-invasive effectors. Consequently, the IL11 Knockout AGS Polyclonal Cells provide a physiologically relevant platform to dissect the contribution of IL-11 to gastric tumor cell-autonomous behaviors and to evaluate the therapeutic benefit of targeting IL-11 signaling in gastric adenocarcinoma.
Typical research applications include gastric cancer biology investigations, cytokine signaling studies, and drug target validation. These polyclonal knockout cells are compatible with a range of assays: Western blotting to assess phosphorylation of STAT3 and ERK1/2; RT-qPCR quantification of fibrotic markers (COL1A1, ACTA2) and matrix metalloproteinases; transwell migration and invasion assays; MTT or similar viability assays; and annexin V apoptosis detection. The cells can also be used in co-immunoprecipitation experiments to examine IL11RA/gp130 complex assembly or in xenograft studies to evaluate tumor growth in vivo. For technical inquiries and ordering information, please contact Ascent Research.
